Hypofibrinogenemia Clinical Trial
Official title:
Efficacy and Safety of Fibrinogen Concentrate (Human) (FCH) for On-demand Treatment of Acute Bleeding in Subjects With Congenital Fibrinogen Deficiency
This is a multinational, multicenter, prospective, open-label historically controlled Phase IIIb non-inferiority clinical trial on the efficacy and safety of Fibrinogen Concentrate (Human). It is estimated that 150-300 patients in the U.S. suffer from afibrinogenemia. Substitution with cryoprecipitate or alternative treatments have limited safety and efficacy. The primary purpose of the study is to demonstrate the hemostatic efficacy of Fibrinogen Concentrate (Human) by adequately controlling acute bleeding (spontaneous or after trauma) in patients with congenital fibrinogen deficiency (afibrinogenemia and hypofibrinogenemia). Cryoprecipitate hemostatic efficacy data from a retrospective physician survey will be used as a historical control.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05780125 -
Effectiveness of Different Fibrinogen Preparations in Restoring Clot Firmness
|
Phase 2 | |
| Recruiting |
NCT03884725 -
Fibrinogen Concentrate In Children Cardiac Surgery 2
|
Phase 4 | |
| Completed |
NCT02822599 -
Human Fibrinogen Concentrate in Pediatric Cardiac Surgery
|
Phase 4 | |
| Recruiting |
NCT05634005 -
Clinical Decision Support for Blood Transfusions to Improve Guideline Adherence
|
N/A | |
| Withdrawn |
NCT04636268 -
FIB Grifols Congenital Deficiency for On-demand Treatment and Surgical Prophylaxis
|
Phase 3 | |
| Recruiting |
NCT05711524 -
Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen to Expedite Product Availability in Perioperative Bleeding
|
Phase 4 |